Active	Status	Sponsor type	Region	Phase	Filter
2 Active 10 Inactive 12 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
varespladib (A-002) / Anthera Pharma, Ophirex
BRAVO, NCT04996264: Broad-spectrum Rapid Antidote: Varespladib Oral for Snakebite	Completed	2	96	US, RoW	Varespladib Methyl, LY333013, Placebo, Standard of care (SOC)	Ophirex, Inc., Premier Research Group plc	Snakebites, Envenoming, Envenoming, Snake, Envenomation, Snake	06/23	06/23
BRAVIO, NCT05717062: Broad-spectrum Rapid Antidote: Varespladib IV to Oral Trial for Snakebite	Recruiting	2	140	US	Varespladib intravenous form, LY315920, varespladib-methyl- oral form, LY333013, Placebo intravenous form, Placebo - oral form	Ophirex, Inc.	Snakebite, Envenoming, Snake	03/25	07/25